SAN FRANCISCO--(BUSINESS WIRE)--Cannabis Science Inc. (NASD OTCBB: CBIS), an emerging pharmaceutical cannabis company, is pleased to announce that the company continues to assemble its team of drug development experts to pilot the company through the regulatory guidelines necessary to gain FDA approval of its first cannabis-based drug.
